Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

被引:43
作者
Durbin, Anna P. [1 ]
Whitehead, Stephen S. [2 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA
[2] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
来源
VIRUSES-BASEL | 2011年 / 3卷 / 10期
基金
美国国家卫生研究院;
关键词
Dengue vaccine; DNA vaccine; vectored-vaccine; sub-unit protein vaccine; NEUTRALIZING ANTIBODY-RESPONSE; GLYCOPROTEIN PROTECT MICE; TETRAVALENT DNA VACCINE; FLAVIVIRUS-NAIVE ADULTS; VIRUS E-GLYCOPROTEIN; IMMUNE-RESPONSES; MONOCLONAL-ANTIBODIES; NONHUMAN-PRIMATES; ADENOVIRUS VECTOR; SUBUNIT VACCINE;
D O I
10.3390/v3101800
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
引用
收藏
页码:1800 / 1814
页数:15
相关论文
共 65 条
[11]   Dengue Vaccine Candidates in Development [J].
Durbin, Anna P. ;
Whitehead, Stephen S. .
DENGUE VIRUS, 2010, 338 :129-143
[12]   Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences [J].
Gibbons, Robert V. ;
Kalanarooj, Siripen ;
Jarman, Richard G. ;
Nisalak, Ananda ;
Vaughn, David W. ;
Endy, Timothy P. ;
Mammen, Mammen P., Jr. ;
Srikiatkhachorn, Anon .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05) :910-913
[13]   Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates [J].
Guirakhoo, F ;
Pugachev, K ;
Zhang, Z ;
Myers, G ;
Levenbook, I ;
Draper, K ;
Lang, J ;
Ocran, S ;
Mitchell, F ;
Parsons, M ;
Brown, N ;
Brandler, S ;
Fournier, C ;
Barrere, B ;
Rizvi, F ;
Travassos, A ;
Nichols, R ;
Trent, D ;
Monath, T .
JOURNAL OF VIROLOGY, 2004, 78 (09) :4761-4775
[14]   THE MURRAY VALLEY ENCEPHALITIS-VIRUS PRM PROTEIN CONFERS ACID RESISTANCE TO VIRUS-PARTICLES AND ALTERS THE EXPRESSION OF EPITOPES WITHIN THE R2 DOMAIN OF E-GLYCOPROTEIN [J].
GUIRAKHOO, F ;
BOLIN, RA ;
ROEHRIG, JT .
VIROLOGY, 1992, 191 (02) :921-931
[15]   Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model [J].
Guy, Bruno ;
Barban, Veronique ;
Mantel, Nathalie ;
Aguirre, Marion ;
Gulia, Sandrine ;
Pontvianne, Jeremy ;
Jourdier, Therese-Marie ;
Ramirez, Laurence ;
Gregoire, Veronique ;
Charnay, Christophe ;
Burdin, Nicolas ;
Dumas, Rafaele ;
Lang, Jean .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (02) :302-311
[16]  
HALSTEAD SB, 2008, VACCINES, P1155
[17]   SYNERGISTIC INTERACTIONS OF ANTI-NS1 MONOCLONAL-ANTIBODIES PROTECT PASSIVELY IMMUNIZED MICE FROM LETHAL CHALLENGE WITH DENGUE-2 VIRUS [J].
HENCHAL, EA ;
HENCHAL, LS ;
SCHLESINGER, JJ .
JOURNAL OF GENERAL VIROLOGY, 1988, 69 :2101-2107
[18]   A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates [J].
Hermida, L ;
Bernardo, U ;
Martín, J ;
Alvarez, M ;
Prado, I ;
López, C ;
Sierra, BDL ;
Martínez, R ;
Rodríguez, R ;
Zulueta, A ;
Pérez, AB ;
Lazo, L ;
Rosario, D ;
Guillén, G ;
Guzmán, MG .
VACCINE, 2006, 24 (16) :3165-3171
[19]   A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice [J].
Hermida, L ;
Rodríguez, R ;
Lazo, L ;
Silva, R ;
Zulueta, A ;
Chinea, G ;
López, C ;
Guzmán, MG ;
Guillén, G .
JOURNAL OF VIROLOGICAL METHODS, 2004, 115 (01) :41-49
[20]   Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes [J].
Holman, David H. ;
Wang, Danher ;
Raviprakash, Kanakatte ;
Raja, Nicholas U. ;
Luo, Min ;
Zhang, Jianghui ;
Porter, Kevin R. ;
Dong, John Y. .
CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (02) :182-189